[go: up one dir, main page]

AU2002233271A1 - Substitued oxazoles and thiazoles as hppar alpha agonists - Google Patents

Substitued oxazoles and thiazoles as hppar alpha agonists

Info

Publication number
AU2002233271A1
AU2002233271A1 AU2002233271A AU3327102A AU2002233271A1 AU 2002233271 A1 AU2002233271 A1 AU 2002233271A1 AU 2002233271 A AU2002233271 A AU 2002233271A AU 3327102 A AU3327102 A AU 3327102A AU 2002233271 A1 AU2002233271 A1 AU 2002233271A1
Authority
AU
Australia
Prior art keywords
substitued
oxazoles
thiazoles
alpha agonists
hppar alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002233271A
Inventor
Michael Lawrence Sierra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2002233271A1 publication Critical patent/AU2002233271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2002233271A 2000-12-20 2001-12-18 Substitued oxazoles and thiazoles as hppar alpha agonists Abandoned AU2002233271A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25707000P 2000-12-20 2000-12-20
US60257070 2000-12-20
PCT/EP2001/014886 WO2002050047A1 (en) 2000-12-20 2001-12-18 Substitued oxazoles and thiazoles as hppar alpha agonists

Publications (1)

Publication Number Publication Date
AU2002233271A1 true AU2002233271A1 (en) 2002-07-01

Family

ID=22974753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002233271A Abandoned AU2002233271A1 (en) 2000-12-20 2001-12-18 Substitued oxazoles and thiazoles as hppar alpha agonists

Country Status (5)

Country Link
US (1) US7091225B2 (en)
EP (1) EP1345916A1 (en)
JP (1) JP2004517100A (en)
AU (1) AU2002233271A1 (en)
WO (1) WO2002050047A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
IL160327A0 (en) * 2001-08-13 2004-07-25 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
MXPA04003398A (en) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activator for peroxisome proliferator-activated receptor delta.
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
KR100474202B1 (en) 2002-05-04 2005-03-08 강헌중 Process for preparing thiazol derivative and the intermediate compounds for preparing the same
HRP20050336B1 (en) * 2002-10-21 2013-06-30 Janssen Pharmaceutica N.V. SUBSTITUTED TETRALINS AND INDANES AND THEIR APPLICATIONS
AU2003279981A1 (en) * 2002-10-21 2004-05-13 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
EP1569897A1 (en) * 2002-10-21 2005-09-07 Janssen Pharmaceutica N.V. Substituted tetralins and indanes
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
ATE463249T1 (en) 2004-08-25 2010-04-15 Essentialis Inc PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENER AND USES THEREOF
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
BRPI0606232A2 (en) * 2005-02-25 2009-06-09 Kang Heonjoong thiazole derivatives such as delta ppar ligands and their production processes
CN103172592B (en) 2006-01-05 2016-01-06 伊森舍丽斯有限公司 Salt of potassium ATP channel opener and uses thereof
EP2061442B1 (en) 2006-09-08 2016-08-31 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
JP2010532383A (en) * 2007-07-02 2010-10-07 エッセンシャリス，インク． Potassium ATP channel opener salts and uses thereof
EP2404430B1 (en) * 2009-03-05 2016-11-02 Telecom Italia S.p.A. Distributed system for storing digital data

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (en) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THESE AS ACTIVE ACTIVE SUBSTANCES
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (en) * 1999-12-02 2001-10-18 Glaxo Group Ltd OXAZOLES AND THIAZOLES REPLACED AS AGONIST OF THE RECEPTOR ACTIVATED BY THE HUMAN PEROXISOMAS PROLIFERATOR
PT1347971E (en) * 2000-12-21 2006-06-30 Bristol Myers Squibb Co TIAHOLYLIC INHIBITORS OF TYROSINE-CINASES OF THE TEC FAMILY

Also Published As

Publication number Publication date
JP2004517100A (en) 2004-06-10
US20040147571A1 (en) 2004-07-29
EP1345916A1 (en) 2003-09-24
US7091225B2 (en) 2006-08-15
WO2002050047A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU2002233271A1 (en) Substitued oxazoles and thiazoles as hppar alpha agonists
GC0000215A (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002314744A1 (en) Thiazole and other heterocyclic ligands and use thereof
AU2002319320A1 (en) Substituted isoxazoles and the use thereof as antibiotics
AU2002349705A1 (en) Azole compound and medicinal use thereof
AU2710301A (en) Novel remedies with the use of beta3 agonist
AU2001233837A1 (en) Benzthiazoles as tnf and pde-iv inhibitors
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2003225756A1 (en) Silica-based materials and methods
AU2001292285A1 (en) Thiazole or oxazole derivatives
AU2001248820A1 (en) Thiazole and oxazole derivatives
ZA200108718B (en) Thiazolidinedione derivative and its use as antidiabetic.
AU2002347985A1 (en) Peroxisome proliferator activated receptor alpha agonists
AU2003299943A1 (en) Heterocycles and uses thereof
AU2001241498A1 (en) Matrix metalloproteinase inhibitors and uses thereof
EP1352336A4 (en) Faster transforms using scaled terms, early aborts, and precision refinements
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2090202A (en) 1, 2, 4-oxadiazole derivatives as hppar alpha agonists
AU2002224772A1 (en) Morphinoid derivatives as delta-opioid agonists and antagonists
AU2001276258A1 (en) Ceramic component and the use thereof
AU2002245127A1 (en) Oxazolidinone photoaffinity probes, uses and compounds
SI1244642T1 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators
AU2002352390A1 (en) Rosiglitazone citrate and its use as antidiabetic
AU2001268103A1 (en) Amorphous oxazole coumpound and its use as cox-2 inhibitor